

Gary K Koski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6560503/publications.pdf>

Version: 2024-02-01

12
papers

554
citations

1040056

9
h-index

1281871

11
g-index

12
all docs

12
docs citations

12
times ranked

659
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. , 2022, 10, e004841.		6
2	Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2pos Breast Cancer. International Journal of Breast Cancer, 2021, 2021, 1-12.	1.2	5
3	Murine Dendritic Cells Grown in Serum-Free Culture Show Potent Therapeutic Activity when Loaded with Novel Th Epitopes in an Orthotopic Model of HER2pos Breast Cancer. Vaccines, 2021, 9, 1037.	4.4	1
4	Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2pos Disease. Vaccines, 2020, 8, 72.	4.4	11
5	Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells <i>in vitro</i> and suppress tumor growth <i>in vivo</i> . Oncotarget, 2020, 11, 2873-2888.	1.8	12
6	Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib. PLoS ONE, 2019, 14, e0210209.	2.5	20
7	T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget, 2019, 10, 6006-6020.	1.8	14
8	Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER ^{pos} /HER2 ^{pos} early breast cancer. OncoImmunology, 2017, 6, e1207032.	4.6	30
9	HER α pulsed dendritic cell vaccine can eliminate HER α expression and impact ductal carcinoma in situ. Cancer, 2012, 118, 4354-4362.	4.1	133
10	STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells. Blood, 2008, 112, 1832-1843.	1.4	45
11	Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. Cancer Research, 2007, 67, 1842-1852.	0.9	247
12	Rapid lipopolysaccharide-induced differentiation of CD14+ monocytes into CD83+ dendritic cells is modulated under serum-free conditions by exogenously added IFN- γ and endogenously produced IL-10. European Journal of Immunology, 2001, 31, 3773-3781.	2.9	30